Baseline characteristics associated with long-term disease control in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer
| Characteristic . | Alpelisib plus fulvestrant . | Placebo plus fulvestrant . | ||
|---|---|---|---|---|
| Patients with long-term disease control (n = 51) . | All patients (n = 169) . | Patients with long-term disease control (n = 38) . | All patients (n = 172) . | |
| ECOG PS 0 | 74.5% | 66.3% | 86.8% | 65.7% |
| Median time from diagnosis to recurrence | 87.4 months | 56.6 months | 73.0 months | 50.7 months |
| Metastatic sites <3 | 82.4% | 71.6% | 73.7% | 65.7% |
| Liver metastases | 15.7% | 29.0% | 13.2% | 31.4% |
| Primary endocrine resistance | 5.9% | 13.6% | 7.9% | 12.8% |
| Characteristic . | Alpelisib plus fulvestrant . | Placebo plus fulvestrant . | ||
|---|---|---|---|---|
| Patients with long-term disease control (n = 51) . | All patients (n = 169) . | Patients with long-term disease control (n = 38) . | All patients (n = 172) . | |
| ECOG PS 0 | 74.5% | 66.3% | 86.8% | 65.7% |
| Median time from diagnosis to recurrence | 87.4 months | 56.6 months | 73.0 months | 50.7 months |
| Metastatic sites <3 | 82.4% | 71.6% | 73.7% | 65.7% |
| Liver metastases | 15.7% | 29.0% | 13.2% | 31.4% |
| Primary endocrine resistance | 5.9% | 13.6% | 7.9% | 12.8% |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, human epidermal growth factor receptor 2; HR, hormone receptor.
Baseline characteristics associated with long-term disease control in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer
| Characteristic . | Alpelisib plus fulvestrant . | Placebo plus fulvestrant . | ||
|---|---|---|---|---|
| Patients with long-term disease control (n = 51) . | All patients (n = 169) . | Patients with long-term disease control (n = 38) . | All patients (n = 172) . | |
| ECOG PS 0 | 74.5% | 66.3% | 86.8% | 65.7% |
| Median time from diagnosis to recurrence | 87.4 months | 56.6 months | 73.0 months | 50.7 months |
| Metastatic sites <3 | 82.4% | 71.6% | 73.7% | 65.7% |
| Liver metastases | 15.7% | 29.0% | 13.2% | 31.4% |
| Primary endocrine resistance | 5.9% | 13.6% | 7.9% | 12.8% |
| Characteristic . | Alpelisib plus fulvestrant . | Placebo plus fulvestrant . | ||
|---|---|---|---|---|
| Patients with long-term disease control (n = 51) . | All patients (n = 169) . | Patients with long-term disease control (n = 38) . | All patients (n = 172) . | |
| ECOG PS 0 | 74.5% | 66.3% | 86.8% | 65.7% |
| Median time from diagnosis to recurrence | 87.4 months | 56.6 months | 73.0 months | 50.7 months |
| Metastatic sites <3 | 82.4% | 71.6% | 73.7% | 65.7% |
| Liver metastases | 15.7% | 29.0% | 13.2% | 31.4% |
| Primary endocrine resistance | 5.9% | 13.6% | 7.9% | 12.8% |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, human epidermal growth factor receptor 2; HR, hormone receptor.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
